The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world’s leading life sciences companies.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 1 working day of receipt of order. If the CD-Rom version purchased, the report will be sent by courier using express service.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.
The initial chapters of this report provide an orientation of deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value.
Chapter 4 provides details on how to approach biopharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where biopharma companies will be present to discuss opportunities face to face.
The main body of the report is provided in chapter 6 providing a infographic visual summary of the company‘s partnering activity since 2010 according to deal type, industry sector, phase of development, and therapy area.
The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and sub-contracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Nocturia - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H1 2019, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape. Nocturia is defined as need...
Botulism - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H1 2019, provides an overview of the Botulism (Infectious Disease) pipeline landscape. Botulism is a rare but serious illness. The cause...
2019-2023 Hong Kong Immunodiagnostic Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
2019-2023 Mexico Immunodiagnostic Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
2019-2023 Singapore Immunodiagnostic Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
2019-2023 Bulgaria Immunodiagnostic Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
2019-2023 Latvia Immunodiagnostic Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
2019-2023 Sweden Immunodiagnostics Market: Supplier Shares and Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic...
21 Companies Make Active Investments in Rett Syndrome Pipeline Drugs The global demand for Rett Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Rett Syndrome pipeline. Companies quickly adapting to the new technologies both independently...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.